Allogene Therapeutics Inc.

30.83+1.25+4.23%Vol 819.41K1Y Perf 31.51%
Apr 13th, 2021 16:00 DELAYED
BID30.83 ASK30.84
Open29.59 Previous Close29.58
Pre-Market- After-Market-
 - -  - -%
Target Price
48.45 
Analyst Rating
Moderate Buy 1.63
Potential %
57.15 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-86 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-22 
Growth Ranking
★★+     51.31
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-32 
Income Ranking
 —    -
Market Cap4.34B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
23.10 
Earnings Date
5th May 2021

Today's Price Range

29.1530.87

52W Range

23.5755.00

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-6.23%
1 Month
-19.88%
3 Months
-0.77%
6 Months
-28.58%
1 Year
31.51%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALLO30.831.25004.23
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.56-0.535.36
Q03 2020-0.55-0.525.45
Q02 2020-0.55-0.533.64
Q01 2020-0.57-0.5012.28
Q04 2019-0.69-0.5815.94
Q03 2019-0.54-0.507.41
Q02 2019-0.47-0.4112.77
Q01 2019-0.41-0.3221.95
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.4812.73Positive
6/2021 QR-0.556.78Positive
12/2021 FY-2.217.53Positive
12/2022 FY-2.551.54Positive
Next Report Date5th May 2021
Estimated EPS Next Report-0.48
Estimates Count12
EPS Growth Next 5 Years %1.00
Volume Overview
Volume819.41K
Shares Outstanding140.65M
Trades Count11.75K
Dollar Volume19.42M
Avg. Volume863.33K
Avg. Weekly Volume688.00K
Avg. Monthly Volume748.92K
Avg. Quarterly Volume878.34K

Allogene Therapeutics Inc. (NASDAQ: ALLO) stock closed at 30.83 per share at the end of the most recent trading day (a 4.23% change compared to the prior day closing price) with a volume of 819.92K shares and market capitalization of 4.34B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 265 people. Allogene Therapeutics Inc. CEO is David D. Chang.

The one-year performance of Allogene Therapeutics Inc. stock is 31.51%, while year-to-date (YTD) performance is 22.15%. ALLO stock has a five-year performance of %. Its 52-week range is between 23.57 and 55, which gives ALLO stock a 52-week price range ratio of 23.10%

Allogene Therapeutics Inc. currently has a PE ratio of -16.20, a price-to-book (PB) ratio of 4.38, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.72%, a ROC of -27.80% and a ROE of -29.29%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Allogene Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.48 for the next earnings report. Allogene Therapeutics Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Allogene Therapeutics Inc. is Moderate Buy (1.63), with a target price of $48.45, which is +57.15% compared to the current price. The earnings rating for Allogene Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Allogene Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Allogene Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.36, ATR14 : 2.33, CCI20 : -169.75, Chaikin Money Flow : -0.16, MACD : -0.09, Money Flow Index : 27.94, ROC : -10.59, RSI : 53.07, STOCH (14,3) : 22.46, STOCH RSI : 0.51, UO : 32.57, Williams %R : -77.54), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Allogene Therapeutics Inc. in the last 12-months were: Alison Moore (Option Excercise at a value of $313 812), Alison Moore (Sold 124 412 shares of value $5 091 582 ), Arie S. Belldegrun (Buy at a value of $6 879 954), Eric Schmidt (Sold 75 000 shares of value $2 575 553 ), Rafael Amado (Sold 16 538 shares of value $651 515 ), Veer Bhavnagri (Option Excercise at a value of $253 105), Veer Bhavnagri (Sold 66 553 shares of value $2 448 087 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (68.75 %)
10 (62.50 %)
9 (60.00 %)
Moderate Buy
0 (0.00 %)
1 (6.25 %)
1 (6.67 %)
Hold
5 (31.25 %)
5 (31.25 %)
5 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.63
Moderate Buy
1.69
Moderate Buy
1.73

Allogene Therapeutics Inc.

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

CEO: David D. Chang

Telephone: +1 650 457-2700

Address: 210 East Grand Avenue, South San Francisco 94080, CA, US

Number of employees: 265

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

62%38%

Bearish Bullish

59%41%

Bearish Bullish

57%43%

News

Stocktwits